

News Releases

All Years



Search

GO

[Advanced Search](#)

Sep 19, 2019

Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry leader with more than 25 years of...

Aug 22, 2019

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual Biotech Conference on Wednesday,...

Aug 13, 2019

Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of \$28.00 per share. In...

Aug 12, 2019

Portola Pharmaceuticals Announces Proposed Offering of Common Stock

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced plans to offer, subject to market and other conditions, \$200 million of its common stock in an underwritten public offering. The...

Aug 7, 2019

Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

- Second Quarter Revenues of \$28.4 Million; Andexxa® Net Product Revenues Grow to \$27.1 Million

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended June 30, 2019, and provided a corporate update. "This is our fifth consecutive quarter of...

Show 5



per

< [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) ... [49](#) >

page



<https://investors.portola.com/news-releases?o=5>